ImmunityBio (IBRX) Aperçu de l'action
ImmunityBio, Inc. est une société de biotechnologie qui se concentre sur l'innovation, le développement et la commercialisation d'immunothérapies de nouvelle génération conçues pour activer le système immunitaire du patient et offrir une protection durable contre le cancer et les maladies infectieuses. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 1/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
IBRX Community Fair Values
Create NarrativeSee what 91 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ImmunityBio, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$8.22 |
| Plus haut sur 52 semaines | US$12.43 |
| Plus bas sur 52 semaines | US$1.95 |
| Bêta | 0.077 |
| Variation sur 1 mois | 15.77% |
| Variation sur 3 mois | 12.60% |
| Variation sur 1 an | 192.53% |
| Variation sur 3 ans | 195.68% |
| Variation sur 5 ans | -24.10% |
| Évolution depuis l'introduction en bourse | -78.76% |
Nouvelles et mises à jour récentes
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.ImmunityBio: A Long-Term Bull Case Worth Watching
Summary ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation. Elevated short interest (38% of float) and international expansion efforts signal heightened volatility and potential for sharp moves as global regulatory milestones approach. Read the full article on Seeking Alpha
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Recent updates
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.ImmunityBio: A Long-Term Bull Case Worth Watching
Summary ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation. Elevated short interest (38% of float) and international expansion efforts signal heightened volatility and potential for sharp moves as global regulatory milestones approach. Read the full article on Seeking AlphaIBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking AlphaRendement pour les actionnaires
| IBRX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -12.9% | -2.3% | 0.8% |
| 1Y | 192.5% | 35.8% | 20.6% |
Rendement vs Industrie: IBRX a dépassé le secteur US Biotechs qui a rapporté 35.8 % au cours de l'année écoulée.
Rendement vs marché: IBRX a dépassé le marché US qui a rapporté 20.6 % au cours de l'année écoulée.
Volatilité des prix
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: IBRX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de IBRX ( 10% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 688 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc. est une société de biotechnologie qui se concentre sur l'innovation, le développement et la commercialisation d'immunothérapies de nouvelle génération conçues pour activer le système immunitaire du patient et offrir une protection durable contre le cancer et les maladies infectieuses. Ses plateformes de développement de produits biologiques et de produits candidats comprennent des protéines de fusion de cytokines, des vecteurs d'ADN et de vaccins, ainsi que des thérapies cellulaires. La plateforme de l'entreprise a généré des agents thérapeutiques premiers chez l'homme qui devraient faire l'objet d'essais cliniques sur des tumeurs liquides et solides.
ImmunityBio, Inc. Résumé des fondamentaux
| IBRX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$8.61b |
| Bénéfices(TTM) | -US$854.53m |
| Recettes(TTM) | US$140.98m |
Le site IBRX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IBRX compte de résultat (TTM) | |
|---|---|
| Recettes | US$140.98m |
| Coût des recettes | US$933.00k |
| Marge brute | US$140.04m |
| Autres dépenses | US$994.58m |
| Les revenus | -US$854.53m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.82 |
| Marge brute | 99.34% |
| Marge bénéficiaire nette | -606.15% |
| Ratio dettes/capitaux propres | -124.7% |
Quelles ont été les performances à long terme de IBRX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/12 14:09 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ImmunityBio, Inc. est couverte par 6 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |